BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

World

Pierre Fabre and XtalPi Partner on AI-Driven Oncology Drug Discovery

Laboratoires Pierre Fabre and XtalPi (XtalPi Holdings Limited, 2228.HK) are pleased to announce an agreement under which they will collaborate on the disco...

November 11, 2026 | News

Sanyou Bio Secures Nearly RMB 100 Million in Series C to Advance AI-Driven Drug R&D

Accelerating the Development of an AI-Driven Ecosystem for Innovative Drug R&D and Translation Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") rece...

November 11, 2026 | News

DeciBio Launches Precision Medicine Market Intelligence Portal with AI Assistant DeciChat

DeciChat synthesizes thousands of data points across primary data sources to deliver deep insights into precision medicine markets instantly. De...

November 10, 2026 | News

KaliVir’s VET3-TGI Regimens Show 71% Response Rate in Advanced Skin Cancers in Early Trial

Preliminary data from intratumoral VET3-TGI presented in oral session at SITC 2026; abstract recognized among SITC’s top 150 abstracts Responses o...

November 10, 2026 | News

Vir Biotechnology’s Hepatitis Delta Combo Suppresses Virus to Undetectable Levels in All 28 Week 96 Completers

Data presented at AASLD The Liver Meeting demonstrated 100% of participants (28/28) who completed Week 96 of combination therapy reached undetectable v...

November 10, 2026 | News

OncoC4 Reports 33% Response Rate for Cesalatamig in Lung Cancer Resistant to PD-(L)1 Therapy

33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refrac...

November 09, 2026 | News

Differentia Bio Reports Clinical Support for AI-Predicted Treatment Strategies in IgG4-Related Disease

From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharma...

November 05, 2026 | News

Zuellig Pharma Acquires Hangzhou Facility to Strengthen Clinical Trial Supply in China

The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across Chi...

November 05, 2026 | News

Minghui Signs Japan Licensing Deal With ASKA Worth Up to $440 Million for Thyroid Eye Disease Therapy

Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") announced that they have entered into an exclusive license agreement fo...

November 05, 2026 | News

APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now

Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...

November 05, 2026 | Analysis

Lonza to Acquire Five US CDMO Sites from Merck KGaA to Double Manufacturing Footprint

Lonza acquires five CDMO manufacturing sites and approximately 1,100 highly skilled employees, more than doubling its US footprint to nine CDMO sites wit...

November 04, 2026 | News

InventisBio’s Nomelcitinib Achieves Over 70% PASI 90 Response in Phase III Psoriasis Trial

InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key s...

November 04, 2026 | News

Alkermes Advances Orexin-Based Depression Treatment into Phase II Clinical Trial

Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants ...

November 02, 2026 | News

Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery

Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...

November 02, 2026 | News

Stay Connected